Arbutus Biopharma’s (ABUS) “Buy” Rating Reaffirmed at Chardan Capital

Arbutus Biopharma (NASDAQ:ABUS)‘s stock had its “buy” rating restated by investment analysts at Chardan Capital in a research note issued on Friday,Benzinga reports. They presently have a $5.00 target price on the biopharmaceutical company’s stock. Chardan Capital’s price objective would indicate a potential upside of 42.86% from the company’s previous close. Chardan Capital also issued estimates for Arbutus Biopharma’s FY2025 earnings at ($0.30) EPS.

Several other equities analysts have also issued reports on ABUS. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price target on shares of Arbutus Biopharma in a research report on Tuesday, January 21st. StockNews.com cut shares of Arbutus Biopharma from a “hold” rating to a “sell” rating in a report on Thursday, March 13th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $5.50.

Arbutus Biopharma Stock Up 7.0 %

NASDAQ:ABUS opened at $3.50 on Friday. Arbutus Biopharma has a twelve month low of $2.30 and a twelve month high of $4.73. The stock has a market cap of $663.22 million, a P/E ratio of -8.14 and a beta of 1.93. The firm’s fifty day simple moving average is $3.34 and its 200 day simple moving average is $3.56.

Arbutus Biopharma (NASDAQ:ABUS) last released its earnings results on Thursday, March 27th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.01. The firm had revenue of $1.57 million during the quarter, compared to analyst estimates of $2.20 million. Arbutus Biopharma had a negative net margin of 1,137.65% and a negative return on equity of 68.18%. On average, analysts expect that Arbutus Biopharma will post -0.39 EPS for the current fiscal year.

Hedge Funds Weigh In On Arbutus Biopharma

A number of hedge funds have recently bought and sold shares of ABUS. Invesco Ltd. grew its stake in shares of Arbutus Biopharma by 5.7% in the fourth quarter. Invesco Ltd. now owns 69,831 shares of the biopharmaceutical company’s stock worth $228,000 after acquiring an additional 3,780 shares during the period. China Universal Asset Management Co. Ltd. boosted its holdings in Arbutus Biopharma by 10.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 40,179 shares of the biopharmaceutical company’s stock worth $131,000 after purchasing an additional 3,870 shares during the last quarter. Clear Harbor Asset Management LLC boosted its holdings in Arbutus Biopharma by 6.7% in the fourth quarter. Clear Harbor Asset Management LLC now owns 79,761 shares of the biopharmaceutical company’s stock worth $261,000 after purchasing an additional 5,000 shares during the last quarter. Teacher Retirement System of Texas grew its position in Arbutus Biopharma by 18.7% in the 4th quarter. Teacher Retirement System of Texas now owns 42,144 shares of the biopharmaceutical company’s stock worth $138,000 after purchasing an additional 6,644 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Arbutus Biopharma by 10.2% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 89,397 shares of the biopharmaceutical company’s stock valued at $292,000 after buying an additional 8,308 shares during the last quarter. Hedge funds and other institutional investors own 43.79% of the company’s stock.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.